VERAXA Biotech updates on pipeline progress, focusing on BiTAC technology and plans for partnerships in cancer therapies.
Quiver AI Summary
VERAXA Biotech AG, a leader in cancer therapy development, announced significant progress in its pipeline and partnerships during the first half of 2026. CEO Dr. Christoph Antz highlighted the growing interest in their innovative BiTAC® technology, which will drive the company's future development, with plans to focus investments primarily on BiTAC-related projects. VERAXA aims to have its first BiTAC-T-cell engager candidate ready for regulatory submission by early 2028, and its pipeline includes several T-cell engagers and bispecific antibody-drug conjugates (ADCs). Additionally, the company is exploring partnerships for its more traditional therapies, including a monoclonal antibody for acute myeloid leukemia. Chief Business Officer Dr. Heinz Schwer expressed optimism about securing initial partnerships, given the strong market interest in novel drug development.
Potential Positives
- VERAXA Biotech has made substantial progress in refining its pipeline and partnering strategy, indicating a strong focus on growth and innovation in the cancer therapy sector.
- The company anticipates introducing its first BiTAC-T cell engager candidate, VXA-102, to IND/CTA readiness by early 2028, showcasing a clear timeline for development that could attract investor interest.
- VERAXA's pipeline includes multiple BiTAC-based therapeutic programs targeting solid tumors, highlighting its commitment to addressing significant medical needs in oncology.
- The positive environment for partnerships in the pharmaceutical industry, as evidenced by successful interactions at the BIO International Partnering Conference, positions VERAXA favorably for securing collaborations that could enhance its growth prospects.
Potential Negatives
- The press release emphasizes the company's focus on its BiTAC technology, which could imply that other pipeline assets may be deprioritized or at risk, potentially limiting diversification in the company's offerings.
- The completion timeline for the first BiTAC-TCE candidate VXA-102 is set for 2028, which may raise concerns regarding the company's short-term revenue generation and development pace.
- There is a strong emphasis on the need for partnerships to advance their pipeline, which may indicate potential weaknesses in the company's ability to independently deliver results.
FAQ
What is VERAXA Biotech's primary focus in 2026?
VERAXA is concentrating on developing its BiTAC technology and expanding its pipeline of cancer therapies throughout 2026.
What are BiTAC-TCE candidates?
BiTAC-TCE candidates are novel T cell engagers designed to treat various solid tumors, with VXA-102 expected to be IND/CTA-ready by 2028.
How many therapeutic programs are in VERAXA's pipeline?
VERAXA's current pipeline consists of four BiTAC-based therapeutic programs primarily targeting solid tumor indications.
What was the outcome of the BIO International Partnering Conference for VERAXA?
The conference provided an opportunity for VERAXA to meet potential partners and strengthen existing discussions, boosting confidence in its platform.
How does VERAXA plan to finance its growth?
VERAXA intends to invest primarily in its BiTAC portfolio while monetizing selected non-BiTAC pipeline assets to support its growth.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
ZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update.
“In the first six months of 2026, we have made substantial progress in honing our pipeline and partnering strategy. We continue to record tangible interest in our novel BiTAC® technology and its applications in building a range of BiTAC-T cell engagers and BiTAC-antibody-drug conjugates,” stated Dr. Christoph Antz, Ph.D., Chief Executive Officer of VERAXA. “BiTAC molecules are expected to dominate our pipeline development efforts in the years to come and mature to be the main value drivers of the company. Therefore, we intend to channel the lion’s share of our investments into our BiTAC portfolio and aim to monetize selected non-BiTAC pipeline assets early to finance its growth. It is our firm goal to have a first BiTAC-TCE candidate VXA-102 IND/CTA-ready by the beginning of 2028.”
The company’s pipeline currently consists of four BiTAC-based therapeutic programs aimed at treating various solid tumor indications. Mirroring the more advanced state of development of the BiTAC-TCE platform, all of these programs are T cell engagers. Complementing our BiTAC portfolio are currently two bispecific ADCs (bs ADCs) with more traditional molecular design. This includes the bsADC program pursued within a strategic partnership with OmniAb, Inc. The formally most advanced program in VERAXA’s portfolio, the Fc-enhanced FLT3-targeting monoclonal antibody VXA-901 for the treatment of acute myeloid leukemia (AML), and the company’s HER2-targeting ADC program are available for partnering.
“Interest in novel technologies and drug development programs in the T cell engager and ADC space continues to be at a record high in the pharmaceutical industry. To benefit from this positive partnering environment, it is crucial to have a clearly differentiated technology, which we have with our BiTAC platform,“ added Heinz Schwer, Ph.D., MBA, Chief Business Officer. “The recent BIO International Partnering Conference turned out to be a well-timed opportunity for us to meet with potential new partners and also to intensify our ongoing discussions. The feedback received at this and other recent industry and scientific events gives as a great level of confidence that, with continued validation of our platform and products, we will be well positioned to secure initial partnerships.”
About VERAXA Biotech AG (NASDAQ: VRXA)
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including conditionally active T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of TCEs, ADCs, and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
For regular updates about VERAXA Biotech, visit www.veraxa.com or follow us on LinkedIn , X (formerly known as Twitter) and Bluesky .
BiTAC® is a registered trademark of VERAXA Biotech GmbH.
Forward-looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that address activities, events, or developments that VERAXA Biotech AG (the "Company") intends, expects, plans, projects, believes, or anticipates will or may occur in the future are forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations, including with respect to the company’s anticipated pipeline development focus, its ability to monetize its pipeline assets, the timing for development of its pipeline candidates and the ability of the company to partner its pipeline assets. No forward-looking statement can be guaranteed. Forward-looking statements contained on this press release should be evaluated together with the many uncertainties that affect the Company's business, particularly those identified in the risk factors section of the Company’s registration statement on Form F-4. These documents are available from the Securities and Exchange Commission, the Company website or from Company Investor Relations.
In addition, any information contained in this press release was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained in this press release and investors should not rely upon the information as current or accurate after the presentation date.
Contact
VERAXA Biotech AG - Corporate
Christoph Antz, Ph.D.
Chief Executive Officer, Co-Founder
[email protected]
For Media and Investors – U.S.
Brandon Weiner
ICR Healthcare
[email protected]
For Media and Investors – EU
Mario Brkulj
[email protected]
Attachment
